Genoskin, a biotechnology company at the forefront of accelerating drug development, proudly announces the enhancement of its ISR Platform® with the integration of AUDACY, a state-of-the-art bioinformatics-based analytical solution. The new ImmunoSafe: ISR Platform® brings a transformative approach to assessing local toxicity in the realm of non-clinical platforms, specifically focusing on injection site reactions (ISR).